Avivagen Inc. announced the completion of a trial testing OxC-betaTM Livestock 10% in dairy cattle conducted by COFCO Biotech of Beijing, China. Because antibiotics are not widely used to enhance productivity in dairy cattle during lactation, this trial has the potential to expand market opportunities of OxC-beta beyond replacement of antibiotics used as growth promoters. Results demonstrated that supplementation with OxC-beta significantly increased protein content of milk by 15.8% and improved several other indicators of milk quality when compared to controls. By improving milk quality, OxC-beta has the potential to provide a benefit to both producers and consumers. Dairy producers receive a premium for high quality milk, which means OxC-beta can help improve the profitability and sustainability of their operations while consumers can benefit from increased nutritional value of the milk. The trial ran for 35-days at a commercial dairy near Beijing, China and evaluated two doses of OxC-beta for the ability to improve productivity and milk quality in lactating dairy cows. The potential benefits of dietary supplementation with OxC-beta were assessed by comparison to a non-supplemented control group.